香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不因本公告全部或任何部份內 容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 海外監管公告 本公告乃上海復旦張江生物醫藥股份有限公司（「本公司」）根據香港聯合交易所有 限公司證券上市規則第 13.10(B)條刊發。 茲載列本公司於上海證券交易所網站刊發的《上海復旦張江生物醫藥股份有限公司關 於持股 5%以上股東減持股份計劃公告》，僅供參閱。該文件及其披露內容乃根據中國 法律法規及境內相關監管要求而編制及刊發。 承董事會命 趙大君 主 席 於本公告刊發日期，董事會包括以下人士： 趙大君先生（執行董事） 中國·上海 二零二五年八月二十七日 *僅供識別 证券代码：688505 证券简称：复旦张江 公告编号：临 2025-028 上海复旦张江生物医药股份有限公司 关于持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 截至本 ...

Market Overview - The net inflow of main funds in the Shanghai and Shenzhen markets reached 25.419 billion yuan, with the Sci-Tech Innovation Board seeing a net inflow of 6.497 billion yuan [1] - A total of 278 stocks experienced net inflows, while 309 stocks faced net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 470 stocks rose, with 6 stocks hitting the daily limit, including Shengmei Shanghai and Yuntian Lefe [1] - 112 stocks declined in value [1] Key Stocks with Significant Fund Inflows - The top three stocks with the highest net inflows were: - SMIC (中芯国际) with a net inflow of 2.579 billion yuan, ranking first [2] - Haiguang Information (海光信息) with a net inflow of 1.459 billion yuan [2] - Lanke Technology (澜起科技) with a net inflow of 481.64 million yuan [2] Stocks with Continuous Fund Inflows - A total of 56 stocks have seen continuous net inflows for more than three trading days, with Huahai Qingke (华海清科) leading at 10 consecutive days [2] - The stocks with the most extended net outflows included Fudan Zhangjiang (复旦张江) with 15 consecutive days of outflows [2] Fund Inflow Rankings - The top stocks by net inflow and their respective data include: - SMIC (中芯国际): 2.579 billion yuan, 12.69% inflow rate, 14.19% increase [2] - Haiguang Information (海光信息): 1.459 billion yuan, 10.97% inflow rate, 20.00% increase [2] - Lanke Technology (澜起科技): 481.64 million yuan, 7.00% inflow rate, 8.70% increase [2] Summary of Fund Outflows - The stock with the highest net outflow was Yingshi Innovation (影石创新) with a net outflow of 332 million yuan and a decline of 4.34% [1] - Other notable outflows included Sainuo Medical (赛诺医疗) and Tiebian Heavy Industry (铁建重工) with outflows of 223 million yuan and 143 million yuan, respectively [1]

Market Overview - The main funds in the Shanghai and Shenzhen markets experienced a net outflow of 30.229 billion yuan, while the Sci-Tech Innovation Board saw a net inflow of 730 million yuan [1] - A total of 252 stocks had net inflows, while 335 stocks had net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 359 stocks rose, with two stocks hitting the daily limit up, including Shengke Communication and Haocen Software, while 218 stocks fell [1] - The top three stocks with the highest net inflow of funds were Haiguang Information (1.084 billion yuan), Han's Laser (837 million yuan), and SMIC (385 million yuan) [1] Continuous Fund Flow - There were 49 stocks with continuous net inflows for more than three trading days, with Huahai Qingke leading at eight consecutive days of inflow [1] - Conversely, 133 stocks experienced continuous net outflows, with Fudan Zhangjiang and Qi Anxin both seeing 13 consecutive days of outflow [1] Top Fund Inflows - The top stocks by net inflow included: - Haiguang Information: 1.084 billion yuan, 14.77% inflow rate, 4.75% increase [1] - Han's Laser: 837 million yuan, 6.76% inflow rate, 8.46% increase [1] - SMIC: 385 million yuan, 4.97% inflow rate, 3.28% increase [1] Notable Outflows - The stocks with the highest net outflows included: - Dongxin Co., Ltd.: 366 million yuan outflow, 3.75% decrease [1] - Sainuo Medical: 305 million yuan outflow [1] - Yishitong: 177 million yuan outflow [1]

Group 1 - The Shanghai Composite Index fell by 0.02% to close at 3727.29 points, while the Hang Seng Index decreased by 0.21% to 25122.9 points [1] - Fudan Zhangjiang's A/H premium reached 183.21%, ranking third among A/H shares [1] - At market close, Fudan Zhangjiang's A-shares were priced at 10.48 yuan, down 1.87%, and H-shares were at 4.02 HKD, down 1.95% [1] Group 2 - Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1] - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a leading innovation enterprise centered on intellectual property [1] - Fudan Zhangjiang has developed competitive advantages in areas such as gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage forms, with new drugs expected to be launched in the market [1] - The company has undertaken several national key science and technology projects, including the "National Key Technology R&D Program," "National High Technology Research and Development Program (863 Program)," and "Major New Drug Creation" projects [1]

Group 1 - The Shanghai Composite Index rose by 0.85% to close at 3728.03 points, while the Hang Seng Index fell by 0.37% to close at 25176.85 points [1] - Fudan Zhangjiang's A/H premium reached 183.79%, ranking third among A/H shares [1] - Fudan Zhangjiang's A-shares closed at 10.68 yuan, with a gain of 2.01%, and H-shares closed at 4.1 Hong Kong dollars, up by 2.24% [1] Group 2 - Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1] - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a knowledge-based innovative enterprise [1] - Fudan Zhangjiang has developed competitive advantages in areas such as gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage technology, with new drugs expected to be launched in the market [1]

Group 1 - The Shanghai Composite Index fell by 0.46% to close at 3666.44 points, while the Hang Seng Index decreased by 0.37% to 25519.32 points [1] - Fudan Zhangjiang's A/H share premium reached 195.57%, ranking second among A/H shares [1] - At market close, Fudan Zhangjiang's A-shares were priced at 10.24 yuan, down 3.31%, and H-shares were at 3.79 HKD, down 3.32% [1] Group 2 - Fudan Zhangjiang Biopharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceuticals Holding Co., Ltd. [1] - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a knowledge-based innovation enterprise [1] - Fudan Zhangjiang has developed competitive advantages in areas such as gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage forms, with new drugs expected to be launched in the market [1]

Core Viewpoint - Fudan Zhangjiang (688505) reported disappointing financial results for the first half of 2025, with a significant decline in both revenue and net profit compared to the previous year [1] Financial Performance - Total revenue for the reporting period was 390 million yuan, a year-on-year decrease of 4.42% [1] - Net profit attributable to shareholders was 5.72 million yuan, down 91.89% year-on-year [1] - In Q2 alone, total revenue was 210 million yuan, a decline of 19.31% year-on-year, with net profit of 3.05 million yuan, down 95.52% [1] - Gross margin was 89.8%, a decrease of 3.22% year-on-year, while net margin was 1.44%, down 91.64% [1] - Total operating expenses (selling, administrative, and financial) reached 202 million yuan, accounting for 51.74% of total revenue, an increase of 55.04% year-on-year [1] Cash Flow and Investment - Operating cash flow per share was 0.06 yuan, an increase of 125% year-on-year [1] - Investment cash flow showed a significant decline of 291.31%, attributed to payments for related engineering projects [6] Changes in Financial Items - Prepayments decreased by 75.51% due to the recognition of expenses based on contract progress [2] - Other equity investments fell by 45.7% due to changes in fair value [2] - Accounts payable decreased by 32.74% due to reduced material payments [3] - Contract liabilities dropped by 56.48% due to decreased advance payments for products [3] - Employee compensation payable decreased by 91.28% as last year's bonuses were fully paid [4] - Tax payable increased by 31.34% due to a higher balance of VAT payable [5] Business Model and R&D Focus - The company's return on invested capital (ROIC) was 1.94%, indicating weak capital returns, with a historical median ROIC of 8.85% since its listing [7] - The company relies heavily on R&D and marketing for its performance, necessitating a thorough examination of these driving factors [7] - The company is advancing several clinical projects, including antibody-drug conjugates for various cancers, with ongoing Phase I and II trials [8][9][10] Future Outlook - The company plans to continue increasing R&D investment in line with the progress of its projects [15] - There is significant potential for the expansion of its products, particularly in the pediatric market [14]

Group 1 - Kaizhong Precision plans to invest up to 250 million yuan to establish a subsidiary and build a production base in Thailand, focusing on overseas connector and precision component business [1] - Longbo Technology reported a 60.18% year-on-year increase in net profit for the first half of 2025, with revenue of 122 million yuan, up 18.03% [2] - Dingyang Technology achieved a net profit of 76.88 million yuan in the first half of 2025, a year-on-year increase of 31.54%, with revenue of 279 million yuan, up 24.61% [4] Group 2 - Heng Rui Pharmaceutical received approval for clinical trials of two drugs, SHR-A2102 and Adebeli monoclonal antibody injection [6] - Maolai Optical plans to use up to 100 million yuan of idle funds for entrusted wealth management to improve fund utilization efficiency [8] - Shiji Information signed a major contract with MGM Grand, providing a next-generation cloud-based hotel information management system [7] Group 3 - Yunnan Germanium's subsidiary received a government subsidy of 6.8 million yuan related to revenue [9] - Jizhi Co. received a warning letter from the Zhejiang Securities Regulatory Bureau for failing to disclose significant government subsidies [10] - Dongfang Precision reported a net profit of approximately 397 million yuan for the first half of 2025, a year-on-year increase of 142.52% [11] Group 4 - Aolaide expects a net profit decrease of 68.41% to 72.77% for the first half of 2025, with revenue projected between 270 million and 290 million yuan [12] - Feilong Co. used 111 million yuan of idle funds for cash management through structured deposit products [13] - Anhui Construction won two major projects with a total investment exceeding 6.6 billion yuan [15] Group 5 - Yunnan Germanium's subsidiary received a government subsidy of 6.8 million yuan related to revenue [9] - Jizhi Co. received a warning letter from the Zhejiang Securities Regulatory Bureau for failing to disclose significant government subsidies [10] - Dongfang Precision reported a net profit of approximately 397 million yuan for the first half of 2025, a year-on-year increase of 142.52% [11] Group 6 - China Medical's subsidiary received approval for the listing of fumaric acid volnora raw materials [20] - Huayuan Vaccine's subsidiary received approval for clinical trials of Hib vaccine [29] - Ganfeng Lithium plans to integrate lithium salt lake projects in Argentina and provide financial support of up to 130 million USD [41]

*注：AH股是指同时在A股和港股上市的公司，溢价（A/H）越大，说明H股相比A股越便宜。 本文源自：金融界 作者：行情君 8月13日，上证指数涨0.48%，收报3683.46点，恒生指数涨2.58%，收报25613.67点。 复旦张江AH溢价达195.54%，位居AH股溢价率第二位。当日收盘，复旦张江A股报10.59元，涨幅 0.67%，H股报3.92港元，下跌1.75%。 资料显示，上海复旦张江生物医药股份有限公司,一九九六年十一月创建于上海浦东张江高科技园区,由 知名企业如上海医药集团股份有限公司等作为公司股东。本着"我们多一分探索、人类多一分健康"的信 念,公司主要从事生物医药的创新研究、开发、生产和销售,力求成为一家以知识产权为核心源泉的生物 医药创新企业。经过多年的不懈努力,公司在基因技术药物、光动力技术药物、纳米技术药物及口服固 体制剂技术药物等领域不断推出新技术及产品,形成了明显的竞争优势,预计未来将陆续有新药投放市 场。凭籍在生物医药领域的实力,公司多次承担"国家重点科技项目(攻关)计划"、"国家高技术研究发展 计划(八六三计划)"、"'重大新药创制'科技重大专项"等。 ...

Core Viewpoint - Fudan Zhangjiang (01349) experienced a nearly 3% decline in stock price following the announcement of its mid-year results for 2025, reflecting a decrease in revenue and profit [1] Financial Performance - The company reported revenue of approximately 390 million yuan, representing a year-on-year decrease of 4.42% [1] - Shareholder profit attributable to the company was 5.715 million yuan, a significant year-on-year decline of 91.89% [1] - Earnings per share were reported at 0.0055 yuan [1] Reasons for Profit Decline - The decline in profit was primarily attributed to an increase in research and development expenses compared to the same period last year [1] - The previous year's results included compensation and penalties related to the termination of cooperation with the promotional service provider, Huizheng (Shanghai) Pharmaceutical Technology Co., Ltd. [1]